Key Points
- Moderna director Noubar Afeyan sold 9,263 shares on May 21 for about $433,878.92, cutting his stake by roughly 70% and leaving him with 3,924 shares.
- Moderna’s latest earnings missed EPS expectations, reporting a loss of $3.40 per share versus the expected $3.02, though revenue of $389 million beat estimates and jumped 260.2% year over year.
- Wall Street remains cautious on Moderna, with analysts assigning an average rating of “Reduce” and a consensus price target of $35.73, despite some recently raised targets.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 9,263 shares of the firm's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the transaction, the director owned 3,924 shares in the company, valued at $183,800.16. The trade was a 70.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Moderna Stock Performance
NASDAQ:MRNA opened at $46.88 on Friday. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $59.55. The firm's fifty day simple moving average is $50.82 and its 200 day simple moving average is $41.59. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $18.60 billion, a PE ratio of -5.75 and a beta of 1.05.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same quarter in the previous year, the business posted ($2.52) earnings per share. The business's quarterly revenue was up 260.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Moderna, Inc. will post -6.74 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on MRNA. Barclays raised their target price on shares of Moderna from $25.00 to $48.00 and gave the company an "equal weight" rating in a research note on Thursday, April 2nd. Jefferies Financial Group set a $37.00 target price on shares of Moderna and gave the company a "hold" rating in a research note on Tuesday, March 3rd. Evercore set a $35.00 target price on shares of Moderna in a research note on Tuesday, February 17th. TD Cowen reiterated a "hold" rating on shares of Moderna in a research note on Thursday, January 29th. Finally, Sanford C. Bernstein reissued a "market perform" rating and issued a $45.00 price target on shares of Moderna in a report on Tuesday, February 17th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of "Reduce" and a consensus price target of $35.73.
Check Out Our Latest Research Report on MRNA
Hedge Funds Weigh In On Moderna
A number of hedge funds and other institutional investors have recently made changes to their positions in MRNA. MUFG Securities EMEA plc bought a new position in shares of Moderna during the 2nd quarter worth about $28,000. Flagship Harbor Advisors LLC bought a new position in shares of Moderna during the 4th quarter worth about $31,000. Canton Hathaway LLC bought a new position in shares of Moderna during the 1st quarter worth about $31,000. Ameriflex Group Inc. lifted its holdings in shares of Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company's stock worth $32,000 after acquiring an additional 1,208 shares during the period. Finally, Cromwell Holdings LLC lifted its holdings in shares of Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company's stock worth $35,000 after acquiring an additional 341 shares during the period. 75.33% of the stock is owned by institutional investors.
Trending Headlines about Moderna
Here are the key news stories impacting Moderna this week:
About Moderna
(
Get Free Report)
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
